XML 53 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Collaborative Arrangements and Licensing Agreements, Biogen (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 188,411 $ 133,791 $ 318,935 $ 275,710  
Biogen Collaborations [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue 97,402 $ 76,887 167,903 $ 170,754  
Deferred revenue $ 323,100   $ 323,100   $ 351,200
Biogen Collaborations [Member] | Revenue [Member] | Strategic Partner [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Concentration percentage 52.00% 58.00% 53.00% 62.00%  
Biogen Collaborations [Member] | Minimum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Cumulative payments received $ 3,600,000   $ 3,600,000    
2013 Strategic Neurology [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue 16,000        
2013 Strategic Neurology [Member] | QALSODY [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Next payment to be achieved $ 20,000   $ 20,000    
2013 Strategic Neurology [Member] | QALSODY [Member] | Minimum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Royalty percentage received on sales of medicine     11.00%    
2013 Strategic Neurology [Member] | QALSODY [Member] | Maximum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Royalty percentage received on sales of medicine     15.00%